Incyte (MEX:INCY) Cyclically Adjusted Revenue per Share: MXN296.79 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INCY Incyte Corp MEX:INCY
83 GF Score
Price MXN2,067.00
GF Value MXN1,817.52
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Cyclically Adjusted Revenue per Share?

Incyte MEX:INCY 83 Cyclically Adjusted Revenue per Share is MXN296.79 as of Mar. 2026. GuruFocus rates MEX:INCY with a GF Score™ of 83/100 and a GF Value™ of MXN1,817.52 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Incyte's adjusted revenue per share for the three months ended in Mar. 2026 was MXN110.960. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN296.79 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Incyte's average Cyclically Adjusted Revenue Growth Rate was 18.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 17.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 20.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Incyte was 36.80% per year. The lowest was -26.20% per year. And the median was 21.00% per year.

As of today (2026-07-19), Incyte's current stock price is MXN2067.00. Incyte's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN296.79. Incyte's Cyclically Adjusted PS Ratio of today is 6.96.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Incyte was 72.80. The lowest was 4.21. And the median was 11.73.


Incyte  (MEX:INCY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Incyte's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2067.00/296.79
=6.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Incyte was 72.80. The lowest was 4.21. And the median was 11.73.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Incyte Cyclically Adjusted Revenue per Share Related Terms


Incyte Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Incyte's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Cyclically Adjusted Revenue per Share Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 152.07 189.43 284.86 278.18 271.77

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 319.17 270.86 281.59 271.77 296.79

MEX:INCY vs INSM, BNTX, ROIV: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Incyte's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted PS Ratio falls into.


MEX:INCY
83GF Score
Incyte Corp MEX:INCY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Incyte's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=110.96/330.2130*330.2130
=110.960

Current CPI (Mar. 2026) = 330.2130.

Incyte Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 23.598 241.018 32.331
201609 26.821 241.428 36.684
201612 34.478 241.432 47.156
201703 37.037 243.801 50.164
201706 28.765 244.955 38.777
201709 32.567 246.819 43.571
201712 41.317 246.524 55.343
201803 32.809 249.554 43.413
201806 47.640 251.989 62.429
201809 38.948 252.439 50.947
201812 48.035 251.233 63.136
201903 44.492 254.202 57.796
201906 46.806 256.143 60.341
201909 49.999 256.759 64.303
201912 50.022 256.974 64.279
202003 61.509 258.115 78.690
202006 72.046 257.797 92.284
202009 62.667 260.280 79.505
202012 71.633 260.474 90.812
202103 55.714 264.877 69.457
202106 63.207 271.696 76.820
202109 75.216 274.310 90.545
202112 79.748 278.802 94.454
202203 65.483 287.504 75.211
202206 81.979 296.311 91.359
202209 73.874 296.808 82.188
202212 80.314 296.797 89.356
202303 64.615 301.836 70.690
202306 72.527 305.109 78.494
202309 70.781 307.789 75.938
202312 75.960 306.746 81.771
202403 64.341 312.332 68.025
202406 87.644 314.175 92.118
202409 114.406 315.301 119.817
202412 118.853 315.605 124.354
202503 108.682 319.799 112.221
202506 115.160 322.561 117.892
202509 124.400 324.800 126.473
202512 132.618 324.054 135.139
202603 110.960 330.213 110.960

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN296.79 mean?
Incyte (MEX:INCY) has a Cyclically Adjusted Revenue per Share of MXN296.79 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Incyte and its competitors.
Is Incyte's Cyclically Adjusted Revenue per Share too high?
Incyte's current Cyclically Adjusted Revenue per Share is MXN296.79. Overall, Incyte has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Cyclically Adjusted Revenue per Share compare to INSM and BNTX?
Incyte's Cyclically Adjusted Revenue per Share of MXN296.79 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Incyte and its competitors. Incyte's current Cyclically Adjusted Revenue per Share is MXN296.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,817.52, compared to a current price of MXN2,067.00 — trading 13.7% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN296.79. Incyte's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Cyclically Adjusted Revenue per Share is MXN296.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN2,067.00 is trading 13.7% above its estimated GF Value™ of MXN1,817.52. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • Cyclically Adjusted Revenue per Share: MXN296.79
  • GF Value™: MXN1,817.52 vs. price of MXN2,067.00 (13.7% above fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
83GF Score

Get the complete analysis for MEX:INCY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,067.00
Price
MXN1,817.52
GF Value